Zenas BioPharma
ZBIO
73 hedge funds and large institutions have $330M invested in Zenas BioPharma in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 5 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
29% more capital invested
Capital invested by funds: $257M → $330M (+$73.3M)
9% more funds holding
Funds holding: 67 → 73 (+6)
3.66% more ownership
Funds ownership: 77.75% → 81.41% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.85M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.59M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.86M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.05M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.32M |
| 2 |
EP
Eversept Partners
New York
|
-$1.17M |
| 3 |
CCM
Catalio Capital Management
New York
|
-$777K |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$348K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$316K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Goldman Sachs
New York
| – | -$189K | -23,957 | Closed |
|
|
SIP
77
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$87K | -10,955 | Closed |
|
|
CF
78
Corebridge Financial
Houston,
Texas
| – | -$59.5K | -7,529 | Closed |
|
ZBIO Hedge Fund Activity: Q2 2025 in Review
73 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q2 2025, worth a combined $330M — up 29% from $257M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ZBIO positions and 5 closed out — a net gain of 6 holders — while 34 added to existing stakes and 12 trimmed.
The largest buyer was Federated Hermes, adding an estimated $6.85M. The largest seller was Rock Springs Capital Management, cutting an estimated $2.32M.
- 73 institutional investors held Zenas BioPharma (ZBIO) as of Q2 2025, up from 67 in Q1 2025.
- Funds reported $330M of Zenas BioPharma stock for Q2 2025, up 29% quarter-over-quarter.
- 11 funds opened new Zenas BioPharma positions in Q2 2025 and 5 closed out, a net change of +6 holders.
- The largest Zenas BioPharma buyer in Q2 2025 was Federated Hermes, an estimated $6.85M added.
- The largest Zenas BioPharma seller in Q2 2025 was Rock Springs Capital Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q2 2025.